NovoCure (NSDQ:NVCR) shares are under pressure this morning after the company reported second-quarter losses that exceeded estimates.
The British firm’s losses fell -26.7% to -$15.5 million, or -17¢ per share, on sales growth of 60.3% to $61.5 million for the three months ended June 30.
Get the full story at our sister site, Drug Delivery Business News.